About Kuveda
Kuveda is a company based in San Jose (United States) founded in 2013.. Kuveda has raised $70 thousand across 1 funding round. Kuveda operates in a competitive market with competitors including Denali Therapeutics, GRAIL, MiRagen, Helix and Color, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$70 K (USD)
in 1 rounds
-
Latest Funding Round
$70 K (USD), Angel Round
Jun 01, 2013
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kuveda
Kuveda has successfully raised a total of $70K through 1 strategic funding round. The most recent funding activity was a Angel Round round of $70 thousand completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Angel Round — $70,000
-
First Round
First Round
(01 Jun 2013)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2013 | Amount | Angel Round - Kuveda | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Kuveda
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kuveda
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kuveda Comparisons
Competitors of Kuveda
Kuveda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, GRAIL, MiRagen, Helix and Color, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Genomic database for clinical research is provided.
|
|
| domain | founded_year | HQ Location |
Cancer care is delivered through a virtual clinic by Color.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Kuveda
When was Kuveda founded?
Kuveda was founded in 2013.
Where is Kuveda located?
Kuveda is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Is Kuveda a funded company?
Kuveda is a funded company, having raised a total of $70K across 1 funding round to date. The company's 1st funding round was a Angel Round of $70K, raised on Jun 01, 2013.
What does Kuveda do?
Kuveda was founded in 2013 in San Jose, United States, within the health technology sector. SaaS tools are offered for examining molecular profiles of cancer patients, including biomarkers, proteins, genes, pathways, and specific molecules. Evidence-based personalized treatment options are supported for oncologists. Curated data from pharmacological, biological, toxicological, and genetic sources are integrated to produce detailed reports on therapeutic possibilities.
Who are the top competitors of Kuveda?
Kuveda's top competitors include GRAIL, Juno Therapeutics and Helix.